Evidence map›Paper›PMID 29611379›Full record

ArticleAnnals of laboratory medicine2018

GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.

Naery Yang, Sholhui Park, Min Sun Cho, Miae Lee, Ki Sook Hong, Yeung Chul Mun, Chu Myong Seong, Hee Jin Huh, Jungwon Huh

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of laboratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Naery YangDepartment of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
Sholhui ParkDepartment of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
Min Sun ChoDepartment of Pathology, College of Medicine, Ewha Womans University, Seoul, Korea.
Miae LeeDepartment of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
Ki Sook HongDepartment of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
Yeung Chul MunDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
Chu Myong SeongDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
Hee Jin HuhDepartment of Laboratory Medicine, Dongguk University Ilsan Hospital, Goyang, Korea. hjhuh@duih.org.
Jungwon HuhDepartment of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, Korea. JungWonH@ewha.ac.kr.
Ewha Womans University · KRDongguk University Ilsan Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to determine GATA1 expression levels to better characterize subgroups in BCR/ABL1-negative myeloproliferative neoplasms (MPNs).

methodsThis study enrolled 49 patients diagnosed as having BCR/ABL1-negative MPN on the basis of the 2016 World Health Organization classification : nine polycythemia vera (PV), 17 essential thrombocythemia (ET), 12 prefibrotic primary myelofibrosis (prePMF), and 11 overt primary myelofibrosis (PMF). Relevant clinical and laboratory data were retrieved from the medical records. The molecular analysis of CALR and MPL mutations and quantification of JAK2 V617F allele burden were performed. GATA1 expression was assessed by an immunohistochemical assay on bone marrow biopsy. GATA1 expression was analyzed serially in 18 patients.

resultsGATA1 expression decreased significantly in PMF compared with that in other subtypes, while no statistical difference was identified between ET and prePMF. GATA1 expression did not differ according to the mutation profiles or the allele burden of JAK2 V617F, but it decreased significantly in patients with overt fibrosis or leukemic transformation.

conclusionsOur results suggest that GATA1 expression is significantly low in PMF and decreases with progressive fibrosis and possibly with leukemic transformation, although our attempt to accurately distinguish between subgroups using GATA1 immunohistochemical approach did not achieve statistical significance. A large patient cohort with long term follow-up is required to evaluate the prognostic value of GATA1 expression.

Indexed as

AllelesBone MarrowCytogenetic AnalysisFusion Proteins, bcr-ablGATA1 Transcription FactorGene ExpressionHumansImmunohistochemistryJanus Kinase 2Myeloproliferative DisordersPolymorphism, Single NucleotidePrimary MyelofibrosisSeverity of Illness IndexThrombocythemia, EssentialFusion Proteins, bcr-ablGATA1 protein, humanGATA1 Transcription FactorJAK2 protein, humanJanus Kinase 2Essential thrombocythemiaGATA1Polycythemia veraPrefibrotic primary myelofibrosisPrimary myelofibrosis

Identifiers

PMID29611379
PMCPMC5895858
OpenAlexW2796083692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.